Managing osteoporosis in post-menopausal women: new guidelines


  • Mary Corcoran
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

The Endocrine Society has published new clinical practice guidelines on the pharmacological management of osteoporosis in post-menopausal women. 

Among the key recommendations are: 

  • Bisphosphonates are recommended as the first-line therapeutic choice for post-menopausal women at high risk of fracture. 
  • Fracture risk should be re-assessed after an individual has been on bisphosphonates for three-five years. 
  • Following re-assessment, women who are on bisphosphonates and are at low-to-moderate risk of fracture should be prescribed a 'bisphosphonate holiday' for up to five years. 
  • Denosumab at a dose of 60 mg subcutaneously every six months is recommended as an alternative initial treatment for those at high risk of osteoporotic fractures. 
  • Fracture risk should be re-assessed in those taking denosumab after five to 10 years. Those who remain at high risk of fractures should either continue denosumab or be treated with other osteoporosis therapies. 
  • Administration of denosumab should not be delayed or ceased without subsequent anti-resorptive or other therapy to prevent a rebound in bone turnover. 
  • Calcium and vitamin D should be used as an adjunct to osteoporosis therapies. 

The guidelines are published in the Journal of Clinical Endocrinology and Metabolism